Keryx Biopharmaceuticals (KERX) Stock: Announces FDA Approval | Falling On Poor Earnings
Keryx Biopharmaceuticals (NASDAQ: KERX) is having an overwhelmingly rough start to the trading session this morning, and for good reason. The company released its earnings for the third quarter, missing expectations. While the company also announced that the FDA has approved one of its treatment candidates, investor concerns with regard to earnings seem to be … Read more